page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us>

Theophylline (Theo-Dur, Elixophyllin, Slo-Phyllin, Theo-Dur Sprinkle, Uniphyl, Slo-Bid, various)

Category:

  • Respiratory

Description:

  • Bronchodilator, antiasthmatic, COPD agent

Indications:

  • Bronchial asthma

  • Reversible bronchospasm of chronic bronchitis and emphysema

  • Apnea and bradycardia of prematurity (non FDA approved)

Contraindications:

  • Tachydysrhythmias; as sole treatment of status asthmaticus

  • Active peptic ulcer disease, seizure disorders

Precautions:

  • Pregnancy category C; no reports of malformations; compatible with breast feeding with precaution that rapidly absorbed preparations may cause irritability in the infant

  • Elderly, CHF, cor pulmonale

  • Hepatic disease, diabetes mellitus

  • Hyperthyroidism, hypertension, active alcoholism, children, neonates

Adverse Reactions (Side Effects):

  • CNS: anxiety, dizziness, headache, insomnia, lightheadedness, muscle twitching, restlessness, seizures

  • CV: dysrhythmias, fluid retention with tachycardia, hypotension, palpitations, pounding heartbeat, sinus tachycardia

  • GI: anorexia, bitter taste, diarrhea, dyspepsia, gastroesophageal reflux, nausea, vomiting

  • GU: urinary frequency

  • RESP: increased rate

  • SKIN: flushing, urticaria

Dosage:

Administered orally, intravenously: Dose based on body weight. When converting to sustained release products, total daily dose remains the same but is divided every 8-24 hours depending on product and dose (doses >1200mg daily should be divided every 8 hours, doses <1200mg daily can be given every 12 hours

  • Adult:   

    • Acute symptoms: PO 5 mg/kg load, maintenance 3 mg/kg every 8 hours (non-smokers), 3 mg/kg every 6 hours (smokers), 2 mg/kg every 8 hours (older patients), 1-2 mg/kg every 12 hours (CHF); IV 5 mg/kg load over 20 minutes, maintenance 0.2 mg/kg/hour (CHF, elderly), 0.43 mg/kg/hour (non-smokers), 0.7 mg/kg/hour (young adult smokers), measure serum level for patients currently receiving theophylline, approximately 0.5 mg/kg theophylline increases serum level 1 mcg/ml

    • Slow titration: PO initial dose 16 mg/kg/day or 400mg daily, whichever is less, doses divided every 6-8 hours

  • PO dosage adjustment after serum theophylline measurement:

    • Serum level 5-10 mcg/ml, maintain dose by 25%, recheck level in 3 days

    • Serum level 10-20 mcg/ml, maintain dosage if tolerated, recheck level every 6-12 months

    • Serum level 20-25 mcg/ml, decrease dose by 10%, recheck level in 3 days

    • Serum level 25-30 mcg/ml, skip next dose, decrease dose by 25%, recheck level in 3 days

    • Serum level > 30 mcg/ml, skip next 2 doses, decrease dose by 50%, recheck level in 3 days

  • Child:   

    • 9-16 years: PO 5 mg/kg load, maintenance 3 mg/kg every 6 hours; IV 5 mg/kg load over 20 minutes, maintenance 0.7 mg/kg/hour

    • 1-9 years: PO 5 mg/kg load, maintenance 4 mg/kg every 6 hours; IV 5 mg/kg load over 20 minutes, maintenance 0.8 mg/kg/hour

    • Infants: PO [(0.2 X age in weeks) +5] X kg = 24 hour dose in mg; divide into every 8 hour dosing (6week to 6 months), every 6 hour dosing (6-12 months); IV 5 mg/kg load over 20 minutes, maintenance dose in mg/kg/hour [(0.0008 X age in weeks) + 0.21]

Drug interactions:

  • Enoxacin, fluoxamine, mexiletine, propranolol, troleandomycin: increased theophylline levels

  • Allopurinol, amiodarone,m cimetadine, ciprofloxacin, disulfiram, erythromycin, interferon alpha, isoniazid, metoprolol, norfloxacin, pentoxyfylline, propafenone, radioactive iodine, tacrine, thiabendazole, ticlopidine, verapamil: increased theophylline levels

  • Smoking: increased theophylline requirements

  • Aminoglutethamide, barbiturates, carbamazepine, phenytoin, rifampin, ritonavir, thyroid hormone: reduced theophylline levels; decreased serum phenytoin levels

 


The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300

This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo

 

 

 

 

 

 

Advertise on this site